Ciprofloxacin as broad-spectrum empiric therapy - Are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: Data from the MYSTIC Program (US)?

Diagnostic Microbiology and Infectious Disease

Volumn 42, Issue 3, 2002, Pages 213-215

  Jones, Ronald N ^a,b   Pfaller, Michael A ^a,b  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CITROBACTER; CONTROLLED STUDY; DIAGNOSTIC TEST; EMPIRICISM; ENTEROBACTER; ESCHERICHIA COLI; HEALTH CENTER; HEALTH SURVEY; HOSPITAL INFECTION; KLEBSIELLA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA; SPECTRUM; STAPHYLOCOCCUS; STREPTOCOCCUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 0036201230     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(01)00343-1     Document Type: Article

References (9)

1. Impact of appropriateness of initial antimicrobial therapy on the outcome of ventilator-associated pneumonia
2. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever
3. Fluoroquinolones: Is there a different mechanism of action and resistance against Streptococcus pneumoniae?
4. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting
5. Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients
6. Are the fluoroquinolones still viable single agent alternatives (MYSTIC Programme, 2000)?
7. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview